{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:10:59Z","timestamp":1770437459358,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.jval.2013.07.005","type":"journal-article","created":{"date-parts":[[2013,9,16]],"date-time":"2013-09-16T08:38:19Z","timestamp":1379320699000},"page":"965-972","source":"Crossref","is-referenced-by-count":28,"title":["Economic Assessment of an Anti-HCV Screening Program in Italy"],"prefix":"10.1016","volume":"16","author":[{"given":"Matteo","family":"Ruggeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Coretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Americo","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jval.2013.07.005_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jval.2013.07.005_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurpub\/ckp001","article-title":"Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection","volume":"19","author":"Sroczynski","year":"2009","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.jval.2013.07.005_bib3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"issue":"4","key":"10.1016\/j.jval.2013.07.005_bib4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/0272989X09353194","article-title":"Markov decision processes: a tool for sequential decision making under uncertainty","volume":"30","author":"Alagoz","year":"2010","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2013.07.005_bib5","unstructured":"ISTAT. Mortality tables. Available at: http:\/\/www.istat.it\/it\/archivio\/22838. [Accessed January 13, 2013]."},{"key":"10.1016\/j.jval.2013.07.005_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2893.2007.00943.x","article-title":"Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders","volume":"15","author":"Nakamura","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jval.2013.07.005_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jmv.20376","article-title":"Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy","volume":"76","author":"Ansaldi","year":"2005","journal-title":"J Med Virol"},{"key":"10.1016\/j.jval.2013.07.005_bib8","unstructured":"ISTAT. Popolazione residente. Available from: http:\/\/demo.istat.it\/. [Accessed August 8, 2012]."},{"key":"10.1016\/j.jval.2013.07.005_bib9","unstructured":"Stroffolini T. Epidemiologia dell\u2019epatite C: dati italiani. Data available in the press review of the Research Hospital De Bellis, Rome. Available from: www.irccsdebellis.it\/html\/rassegna_stampa\/Conv...\/Stroffolini.pdf. [Accessed April 4, 2013]."},{"key":"10.1016\/j.jval.2013.07.005_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s15010-001-1197-4","article-title":"Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in Northern Italy","volume":"30","author":"Campello","year":"2002","journal-title":"Infection"},{"key":"10.1016\/j.jval.2013.07.005_bib11","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1111\/j.1572-0241.2006.00769.x","article-title":"Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis","volume":"101","author":"Kanwal","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jval.2013.07.005_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF03320628","article-title":"Rapporto costo efficacia della terapia peginterferone alfa-2a+ribavirina in confronto a interferone alfa-2b+ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati","volume":"6","author":"Sullivan","year":"2004","journal-title":"PharmacoEconomics Italian Research Articles"},{"key":"10.1016\/j.jval.2013.07.005_bib13","unstructured":"Carosi G, Caporaso N, Gardini I, et al. Epatiti:un\u2019emergenza sommersa. Report presented at the conference Epatiti Summit 2010, Rome 18 May 2010. Available from: http:\/\/www.sosfegato.it\/camo\/onlu\/es\/Documento_indirizzo.pdf. [Accessed April 4, 2013]."},{"key":"10.1016\/j.jval.2013.07.005_bib14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2013.07.005_bib15","unstructured":"Agenzia Italiana del Farmaco. Available from: http:\/\/farmaco.agenziafarmaco.it\/index.php. [Accessed August 8, 2012]."},{"key":"10.1016\/j.jval.2013.07.005_bib16","unstructured":"\u201cRicognizione e primo aggiornamento delle tariffe massime per la remunerazione delle prestazioni sanitarie\u201d. Gazzetta Ufficiale n. 289 del 13 dicembre 2006."},{"key":"10.1016\/j.jval.2013.07.005_bib17","unstructured":"Ministero della Salute. Programmazione Sanitaria e Qualit\u00e0 leggi e documenti-Tariffario in euro delle prestazioni specialistiche, delle protesi e drg. Available from: http:\/\/www.ministerosalute.it\/programmazione\/normativa\/sezNormativa. [Accessed August 8, 2012]."},{"key":"10.1016\/j.jval.2013.07.005_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/gut.52.3.425","article-title":"German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"52","author":"Siebert","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jval.2013.07.005_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/0272989X0002000409","article-title":"A comprehensive league table of cost utility ratios and a sub-table of \u201cpanel worthy\u201d studies","volume":"20","author":"Chapman","year":"2000","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2013.07.005_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF03320630","article-title":"Come valutare i risultati di uno studio farmacoeconomico?","volume":"6","author":"Lucioni","year":"2004","journal-title":"PharmacoEconomics - Italian Res Articles"},{"key":"10.1016\/j.jval.2013.07.005_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF03320605","article-title":"Controvalore economico del farmaco e beneficio clinico: stato dell\u2019arte della metodologiae applicazione di un algoritmo farmacoeconomico","volume":"5","author":"Messori","year":"2003","journal-title":"Pharmacoeconomics - Italian Res Articles"},{"key":"10.1016\/j.jval.2013.07.005_bib22","unstructured":"HBV and HCV in the EU neighbourhood: prevalence, burden of disease and screening policies. Full text available for download from the ECDC\u2019s website: Available from: http:\/\/www.ecdc.europa.eu\/en\/publications\/Publications\/Forms\/ECDC_DispForm.aspx?ID=560). [Accessed April 5, 2013]."}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301513019037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301513019037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,13]],"date-time":"2018-10-13T02:27:08Z","timestamp":1539397628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301513019037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1098301513019037"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2013.07.005","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}